Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2024-02-28 Audit Report / Informat…
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
Audit Report / Information 2023
Audit Report / Information Classification · 99% confidence The document explicitly contains the title 'Auditor´s report Annual accounts at December 31, 2023' and the main heading 'Independent auditor's report on the annual accounts'. It details the auditor's opinion on the annual accounts, discusses key audit matters (like deferred tax assets and impairment of investment), and references specific notes to the annual accounts. This content is characteristic of a formal Audit Report, which includes the auditor's opinion on the financial statements. While it relates to the annual accounts, the primary focus and structure presented here are that of the auditor's findings and opinion, fitting the 'Audit Report / Information' category (AR) better than the comprehensive 'Annual Report' (10-K) which is prepared by management. Since it is the full report content and not just an announcement of its publication, AR is the most appropriate classification. FY 2023
2024-02-28 English
Audit Report / Information 2023
Audit Report / Information Classification · 98% confidence The document explicitly contains the title "Auditor´s report Consolidated annual accounts at December 31, 2023" and the section header "Independent auditor's report on the consolidated annual accounts". It details the auditor's opinion, basis for opinion, and key audit matters concerning the consolidated annual accounts for the year ended December 31, 2023. This content is characteristic of an Audit Report, although it is presented alongside the full annual accounts information (which would typically be a 10-K). However, the primary focus and structure presented here are that of the formal auditor's opinion and report on those accounts. Given the definitions, 'Audit Report / Information (AR)' is the most fitting category for a document dominated by the auditor's findings on the financial statements, distinct from the comprehensive '10-K' which includes all management discussion and exhibits, or an 'ER' which is just the release highlights. Since the text includes the full scope of the auditor's report on the consolidated accounts, AR is the best fit, as it covers standalone audit reports and applied accounting principles. FY 2023
2024-02-28 Spanish
Annual Report 2023
Annual Report Classification · 100% confidence The document contains detailed consolidated annual financial statements including balance sheet, income statement, cash flow statement, and notes for the fiscal year ended December 31, 2023. It includes comprehensive financial data, management discussion, and notes integral to the annual accounts. The presence of full financial statements and extensive notes indicates this is the official yearly report covering company activity and full financial performance. The document length (15,000 characters) and content confirm it is not a brief announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-02-28 Spanish
Sylentis, filial de Pharma Mar, informa que el ensayo clínico de fase III con tivanisiran en pacientes con enfermedad de ojo seco asociada al Síndrome de Sjögren no ha alcanzado su objetivo primario.
Legal Proceedings Report Classification · 99% confidence The document is a formal communication dated February 9, 2024, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - Spanish Securities Market Commission). It is explicitly titled 'INFORMACIÓN PRIVILEGIADA' (Inside Information) and announces the results of a Phase III clinical trial for a drug (SYL1001\/V). It states that the primary efficacy objective was not met. Crucially, it mentions: 'Se adjunta nota de prensa que será distribuida a los medios de comunicación en el día de hoy' (A press release that will be distributed to the media today is attached). The document itself contains the core announcement and the full press release text. Since this is a mandatory disclosure of material, non-public information to the regulator, and it contains the full details of the event (not just an announcement that a report is coming), it is best classified as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were quarterly results, but since it's specific clinical trial news, RNS is the most appropriate catch-all for mandatory, non-standard report disclosures in this context, especially given the CNMV header and 'Información Privilegiada' designation. However, looking closely at the definitions, this is a specific announcement of a major corporate event (clinical trial results) that is being disseminated via a press release format to the regulator. This type of material event disclosure often falls under RNS, as it is not a standard periodic report (10-K, IR) or a management discussion (MDA). Given the context of mandatory disclosure of material, non-public information to the regulator, RNS (Regulatory Filings) is the best fit as a specific category is not provided for clinical trial updates, and it is not an ER (which is usually for financial performance).
2024-02-09 Spanish
La Sociedad informa de las operaciones de adquisición de acciones propias en el periodo transcurrido entre el 1 de enero y el 31 de enero de 2024. Finalización de la Adquisición de Acciones Propias y
Transaction in Own Shares Classification · 100% confidence The document is a formal communication dated January 31, 2024, addressed to the Spanish regulator (Comisión Nacional del Mercado de Valores - CNMV). The content explicitly reports on the execution of share repurchase operations ('Adquisición de Acciones Propias') conducted between January 1, 2024, and January 31, 2024. It details the number of shares bought and the prices, and confirms the completion of the buyback program. This activity falls directly under the definition of a company reporting transactions in its own shares. Therefore, the appropriate classification is Transaction in Own Shares (POS).
2024-01-31 Spanish
La Sociedad informa de cambios en la presidencia de la Comisión de Nombramientos y Retribuciones y de Sostenibilidad.
Board/Management Information Classification · 98% confidence The document is a formal communication dated January 30, 2024, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. The content explicitly states it is 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and details the appointment of a new chairperson for the Appointments and Remuneration and Sustainability Committee by the Board of Directors of Pharma Mar, S.A. This action involves a change in senior governance roles (Board/Committee leadership). This directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2024-01-30 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.